Several pharma companies have thrilled investors with their sunny predictions of how the new business-friendly tax package will boost investors’ fortunes this year—but not Amgen. Disappointing fourth-quarter sales and earnings overshadowed the news that Amgen is planning a boatload of new investments.Original Article
Amgen sinks after Q4 earnings miss despite tax benefits and plan for U.S. plant
